<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The uptake of drugs from the blood into the renal tubular cells is a key determinant for renal secretion and may influence their systemic plasma concentrations and extrarenal effects </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi>, used for treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, is taken up into renal tubular cells by the <z:chebi fb="0" ids="25697">organic cation</z:chebi> transporter 2 (OCT2) </plain></SENT>
<SENT sid="2" pm="."><plain>Because many patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> receiving <z:chebi fb="0" ids="6801">metformin</z:chebi> are concomitantly treated with beta-blockers, we tested whether beta-blockers can inhibit OCT2-mediated drug transport </plain></SENT>
<SENT sid="3" pm="."><plain>METHOD: Using Madin-Darby canine kidney II cells stably expressing the uptake transporter OCT2, we analysed whether the beta-blockers <z:chebi fb="0" ids="3127">bisoprolol</z:chebi>, <z:chebi fb="0" ids="3441">carvedilol</z:chebi>, <z:chebi fb="0" ids="6904">metoprolol</z:chebi> and <z:chebi fb="2" ids="8499">propranolol</z:chebi> inhibit the transport of OCT2 substrates 1-<z:chebi fb="36" ids="29309">methyl</z:chebi>-4-phenylpyridinium (<z:chebi fb="26" ids="34761">MPP</z:chebi>(+)) and <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Neither <z:chebi fb="0" ids="3127">bisoprolol</z:chebi> nor <z:chebi fb="0" ids="6904">metoprolol</z:chebi> significantly inhibited the uptake of <z:chebi fb="26" ids="34761">MPP</z:chebi>(+), whereas a significant inhibition was observed for <z:chebi fb="0" ids="3441">carvedilol</z:chebi> und <z:chebi fb="2" ids="8499">propranolol</z:chebi> (half maximal inhibitory concentration IC(50): 26.3 and 67.5 microM) respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, <z:hpo ids='HP_0000001'>all</z:hpo> beta-blockers significantly inhibited OCT2-mediated <z:chebi fb="0" ids="6801">metformin</z:chebi> uptake (IC(50) for <z:chebi fb="0" ids="3127">bisoprolol</z:chebi>: 2.4 microM, IC(50) for <z:chebi fb="0" ids="3441">carvedilol</z:chebi>: 2.3 microM, IC(50) for <z:chebi fb="0" ids="6904">metoprolol</z:chebi>: 50.2 microM and IC(50) for <z:chebi fb="2" ids="8499">propranolol</z:chebi>: 8.3 microM) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: These in vitro results demonstrate that alterations of uptake transporter function by beta-blockers have to be considered as potential mechanisms underlying drug-drug interactions in the kidney </plain></SENT>
</text></document>